Keros Therapeutics (NASDAQ:KROS) Receives “Overweight” Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note published on Wednesday morning, Benzinga reports. They currently have a $105.00 price target on the stock.

KROS has been the topic of a number of other research reports. Wedbush reissued an outperform rating and issued a $86.00 price objective on shares of Keros Therapeutics in a research note on Thursday, February 29th. Truist Financial reaffirmed a buy rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 13th. HC Wainwright reaffirmed a buy rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Friday, March 1st. William Blair reaffirmed an outperform rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Finally, Wells Fargo & Company began coverage on Keros Therapeutics in a research note on Friday, December 8th. They set an overweight rating and a $60.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $86.00.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $64.66 on Wednesday. The firm has a market cap of $2.33 billion, a P/E ratio of -12.43 and a beta of 1.28. The business’s fifty day moving average is $61.33 and its two-hundred day moving average is $43.75. Keros Therapeutics has a 52 week low of $27.02 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Friday, March 1st. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $0.14 million during the quarter. During the same quarter in the prior year, the company posted ($1.09) earnings per share. On average, equities research analysts predict that Keros Therapeutics will post -5.11 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KROS. Point72 Hong Kong Ltd bought a new stake in Keros Therapeutics in the second quarter valued at about $28,000. Almanack Investment Partners LLC. bought a new stake in Keros Therapeutics in the third quarter valued at about $32,000. Osaic Holdings Inc. bought a new stake in shares of Keros Therapeutics in the second quarter worth about $36,000. Tower Research Capital LLC TRC increased its holdings in shares of Keros Therapeutics by 134.6% in the first quarter. Tower Research Capital LLC TRC now owns 1,140 shares of the company’s stock worth $48,000 after acquiring an additional 654 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of Keros Therapeutics during the first quarter worth about $67,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.